At Insilico Medicine, human chemists still synthesize AI-proposed drugs, create variants, and test them on animals, and CEO Alex Zhavoronkov said those human contributors are the people who will be named on the patent.
Sources
- MIT Technology Review (technologyreview.com)
- https://www.artiverse.ca/the-five-human-names-behind-an-ai-designed-drug/ (artiverse.ca)
- https://bioethics.com/archives/103865 (bioethics.com)
- https://www.businessstory.org/2026/08/21/when-ai-designs-a-drug-who-gets-the-credit/ (businessstory.org)
More in Technology
- Around 2022, the Mayo Clinic began digitizing 12 million archived pathology slides using a robot capable of processing up to 1 million samples per month.
- Lytro's light-field camera captured the angle of light rays in addition to color and intensity, allowing users to change a photograph's focus after it was taken, and the company shut down in 2018.
- Fewer than 10% of pathology practices in the United States are digitized, according to Andrew Norgan of the Mayo Clinic.
- OpenAI is testing a 'persistent' Codex agent that can continue working until it is 'put to sleep' and can generate follow-up tasks without prompting.
- The NSA collaborated with the Cybersecurity and Infrastructure Security Agency (CISA) on the '2026 Minimum Elements for a Software Bill of Materials (SBOM)'.
- On classifying tumors from prostate cancer biopsies, Atlas's score was only 70.5%, despite exceeding the other models' highest scores on that task.